MYC and cancer: For example, pharmacological inhibition of MYC-driven GLS by CB-839 has recently shown encouraging results in suppressing various cancers in vitro and in vivo (107–109), and currently examined in a phase 1 clinical trial of solid tumors (NCT02071862).